137 results about "Drug assay" patented technology

The invention relates to an application of inductively coupled plasma mass spectrometry in drug testing of hemin. A method for measuring concentration of stable isotope iron in animal plasma is carried out by an ICP-MS (Inductively Coupled Plasma Mass Spectrometry) method and comprises the following steps of: providing an inductively coupled plasma source mass spectrometer; determining operating conditions of the ICP-MS; providing stable isotope iron powder, marked hemin, internal standard elements and the like; preparing standard solution and internal standard solution; preparing ICP-MS diluent; establishing a standard curve; measuring the stable isotope iron concentration in the plasma; and adding the ICP-MS diluent into a sample tube containing animal plasma sample containing iron, mixing uniformly and putting the sample tube into a refrigerator to be refrigerated, and determining the concentration of the iron in the plasma by the obtained standard curve. The application of the inductively coupled plasma mass spectrometry in the drug testing of the hemin has well performances, e.g., the method has well quantification lower limit, accuracy, absolute recovery test, sample stability, medium effect and quality control requirement, and can be taken as a content measurement method for analyzing the content of the stable isotope iron in a biological sample such as the plasma.

The invention discloses a method for determination of illegally added substances in traditional Chinese medicines and health-care products; with use of high performance liquid chromatography-tandem quadrupole linear ion trap mass spectrometry, the method which is capable of simultaneously qualitative and quantitative detection (multiple reaction monitoring sMRM-information dependent acquisition IDA-enhanced product ion scanning EPI detection) of 13 kinds of illegally added hypoglycemic hypotensive chemical drugs such as clonidine hydrochloride and gliclazide in the traditional Chinese medicines and the health-care products is developed. And through one-time sampling detection, not only can a quantitative result obtained, but also occurrence of a false positive result is effectively avoided through qualitative database screening. The establishment of the method provides a technical support for enacting detection standards of the illegally added hypoglycemic hypotensive chemical drugs in the traditional Chinese medicine and the health-care products.

The invention provides drug assays, methods of diagnosing, and methods and compositions for treating asthma and other lung disease based upon the identification and/or use of agents which modulate CST1, HDAC9 or PRR4 levels or activity.

The invention belongs to the technical field of drug detection and judicial identification, and in particular relates to the detection of seven abused drugs amphetamine, methamphetamine, methylenedioxyamphetamine, methylenedioxy The method for extracting and measuring methamphetamine, ketamine, pethidine and methadone uses methanol as a dispersant and a protein precipitation solvent, uses dichloromethane as an extraction solvent, and forms a microemulsion system of a three-solvent system in an aqueous solution of pH 13, With the assistance of ultrasound, it is further emulsified for liquid-liquid microextraction, and the extraction process does not need to evaporate the extraction solvent; this method has high enrichment multiple and recovery rate, simple and fast operation, high sensitivity, strong specificity, wide linear range and It has the advantages of low cost and environmental friendliness, and can meet the characteristics of urgent judicial appraisal tasks and high requirements for detection time. The detection system of the invention provides a new technical platform for drug detection.

The invention belongs to the technical field of drug detection, and particularly relates to a method and a kit for detecting 19 drugs and metabolites thereof in blood through liquid chromatography-tandem mass spectrometry. The substances to be detected comprise sulpiride, pentafluridol, mianserin, buspirone, tandospirone, hydroxyazine, diazepam, venlafaxine, moclobemide, imipramine, paroxetine, reboxetine, amitriptyline, sertraline, digoxin, clonazepam, clopidogrel, toluenesulfobutyl urea, glimepiride, 1-pyrimidinepiperazine, desmethylvenlafaxine, 6-hydroxy buspirone and normipramine, and the substances to be detected are selected from the group consisting of sulpiride, pentafluridol, mianserin, venlafaxine, metandospirone, metandospirone, hydroxazine, diazepam, venlafaxine, moclobemide, the pharmaceutical composition is prepared from noramitriptyline, nordiazepam and clopidogrel metabolite; the detection method comprises the following steps: calibrating a standard solution, treating a to-be-detected sample, and detecting the to-be-detected sample by adopting high performance liquid chromatography-mass spectrometry. The embodiment of the invention can quickly and accurately measure the content, and the sample treatment method is simple and easy to implement, high in sensitivity and accurate in quantification.

The invention relates to the field of biological detection and discloses a detection device and a detection method of a large class of beta-agonists drugs by applying an immune chromatography technology. According to the invention, an antibody/receptor which is reacted with a large class of the beta-agonists drugs is used for preparing an immune chromatography test strip to realize the simultaneous detection of a large class of the beta-agonists drugs. Compared with the prior art, the detection on a large class of the beta-agonists drugs for one time can be realized, the detection cost is low and the method is convenient and fast.

The invention discloses a method for detecting residue of sodium pentachlorophenate, which belongs to the technical field of drug detection. The method for detecting the residue of the sodium pentachlorophenate comprises the following steps: extracting residue of sodium pentachlorophenate in a sample by utilizing sulfuric acid and normal hexane, and then detecting by utilizing a high performance liquid chromatography-mass spectrometry, wherein the concentration of the sulfuric acid solution is 6 percent. The method has the beneficial effects that the method is suitable for detecting the residue of various matrix sodium pentachlorophenate, the used reagent is low in cost and small in toxicity, impurities can be effectively removed, and the operation steps can be simplified; and by adopting the high performance liquid chromatography-mass spectrometry, compared with the single high performance liquid chromatography, the method has the advantages of high sensitivity, good repetition and low detection limit.

The invention relates to an in-vivo drug testing system based on a nanoparticle modified hollow-core optical fiber. The system comprises a spectrograph, the hollow-core optical fiber, a laser light source, a lens combination optical path and a computer, wherein the hollow-core optical fiber is the nanoparticle modified hollow-core optical fiber; the laser light source is connected with the hollow-core optical fiber by the output end of the lens combination optical path; one end, modified by nanoparticles, of the hollow-core optical fiber is inserted into a body; the other output end of the lens combination optical path is connected with the spectrograph and the spectrograph is connected with the computer; laser is used for stimulating in-vivo drug molecules to generate optical signal information; then the optical signal information is transmitted to the lens combination optical path through the hollow-core optical fiber and then is transmitted to the Raman spectrograph by the lens combination optical path; and content change information of drugs is judged by analyzing a spectrum through the computer. The system can be used for in-vivo drug testing of animals, human bodies and the like, and provides technical supports for individualized medicines, scientific researches and drug development.

This invention provides a system for modeling neurodegenerative and other diseases through somatic gene transfer. In addition, methods of multiple gene transfer, disease analysis and drug testing are provided for.

The invention discloses a method for detecting concentrations of polymyxin B1 and polymyxin B2 in serum, and belongs to the technical field of drug detection. The method comprises the following stepsof: taking pretreated serum, separating an object to be detected from a serum matrix by using ultra-high performance liquid chromatography, and calculating the contents of the polymyxin B1 and the polymyxin B2 by using a mass spectrum internal standard quantitative method according to an established calibration curve. The method disclosed by the invention is high in sensitivity, strong in specificity, accurate and simple in pretreatment process; the separation and the detection of the polymyxin B1 and the polymyxin B2 in the serum are completed within 5.0 minutes; the accuracy and precision basically meet the requirements; the method can be used for quantitatively analyzing polymyxin B1 and polymyxin B2 drugs in serum clinically; and a simple and rapid detection method is provided for monitoring the concentrations of the polymyxin B1 and polymyxin B2 drugs clinically.

The invention provides a novel all-in-one sampling detector for DNA sample collection and saliva alcohol and drug detection. The all-in-one sampling detector consists of a sampling detection rod and adrug detection card, wherein the sampling detection rod is used for saliva and DNA sample collection and alcohol detection. According to the invention, a detection card which can be used for detection of a drug in a saliva sample is prepared based on colloidal gold competitive inhibition method immunochromatography. The all-in-one sampling detector provided by the invention is convenient to use and simple to operate, and can complete DNA sample collection and detection of three indicators of saliva alcohol content while completing drug saliva detection. This product is simple in structure andsmall in size, is suitable for on-site use during law enforcement, and is also suitable for individuals and families to use at any time; painless collection is realized without any trauma or invasiveness, so that a user does not feel any discomfort; the detector is disposable, and has no risk of cross-infection. The collected DNA sample is suitable for genetic analysis and detection and other medical examination.

The invention relates to the technical field of drug detection, and provides a method for determining four diester aconitum alkaloids in blood in order to solve the problems of many interferents, longdetection time and low accuracy of an aconitum alkaloid detection method. The method comprises the following steps: (1) adding a stabilizer into a plasma sample, and storing the plasma sample at lowtemperature for later use; (2) adding an extraction solvent for extraction to obtain an extracting solution; (3) adding a magnetic graphene-based adsorbent for purification treatment to obtain a purified solution; and (4) filtering the purified liquid, and performing HPLC-MS/MS on-machine detection and analysis. According to the invention, the method for detecting four diester aconitum alkaloids in a blood sample is established through pretreatment of a blood sample and optimization of detection conditions, the method is rapid and accurate, the result is objective and easy to analyze, the content change of the four diester aconitum alkaloids in a poisoned patient can be monitored in real time, and a scientific basis can be provided for clinical diagnosis and treatment of aconitum alkaloidpoisoning.

Disclosed herein are embodiments of methods for detecting the presence of and amount of drugs in a sample, particularly a particle sample obtained from a subject. In particular disclosed embodiments, the particle samples are skin particle samples, saliva particle samples, and/or mucous samples isolated from a subject and analyzed using thermal desorption methods combined with a selected detection method.

The invention belongs to the technical field of drug detection, and particularly relates to a method for directly determining three degradation products of tryptophan in a compound amino acid injection. The three degradation products of tryptophan refer to dioxindole alanine, kynurenine and 2-hydroxytryptophan. The method comprises the following specific steps: (1) preparing the following chromatographic conditions of a liquid chromatograph: a chromatographic column being an octadecylsilane chemically bonded silica chromatographic column; a mobile phase comprising a mobile phase A being a phosphate buffer solution and a mobile phase B being acetonitrile; the flow rate being 0.95-1.05 mL/min; the column temperature being 25-35 DEG C; the sample size being 5-100 [mu]L; gradient elution; andthe detection wavelength being 254 nm; (2) preparing a test solution; (3) preparing a reference substance solution; and (4) determining. The method has the advantages of strong specificity, high sensitivity and good repeatability, solves the technical problems of interference of other amino acid components in the prescription, inaccurate determination result caused by derivative reaction in otherdetection methods, and the like, and ensures the product quality.

The invention relates to the technical field of drug detection, and particularly discloses a method for detecting a residual solvent in antiangitide by using a gas chromatographic method and application. According to the method for detecting the residual solvent in antiangitide by utilizing the gas chromatographic method, the residual solvent is dimethyl sulfoxide, a direct sample injection mode is adopted, and a programmed heating mode is as follows: the initial temperature is 50-60 DEG C and is kept for 1-2 minutes; and heating is performed to 210-220 DEG C at the heating rate of 20 DEG C/min, the temperature is kept for 4-6 minutes, and the process is finished after 13-16 minutes. The gas chromatographic detection method is high in sensitivity and good in specificity, stability and accuracy, the quality of antiangitide can be effectively controlled, and the quality of antiangitide is stable, controllable and safe.

The invention provides a tubular tissue structure body and a constructing method thereof. The method comprises the following steps: A, preparing printing ink; B, culturing cells for printing in vitroto obtain a cell culture solution; and C, respectively connecting the printing ink and the cell culture solution with different spray heads of a biological printer, jointly printing the printing ink and the cell culture solution on a winding rod to form seamless tubular tissue, and then removing the winding rod to obtain the hollow tubular tissue structure body. According to the method, a tubularstructure with a controllable structure and cell/material components is formed through a horizontal winding type cell 3D printing technology. The tubular structure is close to a human vessel in shapeand size, has mechanical and biological properties meeting the requirements of a human body, has clinical application potential, and can be applied to the aspects of drug detection, tissue engineering, regenerative medicine, in-vitro physiological model/pathological model/pharmacological model construction, tissue/organ/human body chips and the like.

The invention discloses a reagent detection kit for detecting various drugs for drug alert, and relates to the field of drug alert. The reagent detection box for detecting various drugs for drug alert comprises a refrigeration box body, a first fixing seat and a second fixing seat are fixedly connected to the inner wall of the refrigeration box body and the inner wall of a reaction box body respectively, and a plurality of reagent insertion holes are formed in the upper surface of the first fixing seat and the upper surface of the second fixing seat; the outer surfaces of the top ends of the reagent tubes are movably sleeved with limiting lantern rings; and the lifting mechanism is in transmission connection with two of the limiting lantern rings. According to the reagent detection box for drug warning for detection of various drugs, the semiconductor chilling plate and the heating plate are arranged, the semiconductor chilling plate has a refrigeration effect on reagent tubes placed in the reagent insertion holes, the lifting mechanism is arranged, the reagent tubes are moved to a proper height, and at the moment, marks on the outer surfaces of the reagent tubes can be observed.

The invention discloses a method for determining lidocaine hydrochloride related substances by high performance liquid chromatography, and relates to the field of drug detection, the chromatographic conditions are as follows: octadecylsilane chemically bonded silica bonded with polar groups is selected as a filler as a stationary phase; wherein the particle size of the chromatographic column is 5[mu]m, the detection wavelength ranges from 225 nm to 235 nm, the flow rate is 0.8 to 1.2 ml/min, the column temperature is 30-40 DEG C, and the mobile phase is prepared from the following componentsin parts by mass: 50-80 parts of 0.035 mol/L phosphate buffer solution and 20-50 parts of organic solvent. The adopted detector is a high performance liquid chromatograph, more impurities can be detected by the method, and methodological verification proves that the detection result is accurate and reliable.

The invention belongs to the field of drug detection, and particularly relates to a method for determining photodegradation impurities in a levofloxacin raw material and a levofloxacin preparation. The method comprises the following steps: (1) preparing a levofloxacin photodegradation impurity standard solution; (2) injecting the standard solution into a high performance liquid chromatograph for determination, and constructing a standard curve by taking the concentration of the standard solution as an abscissa and the peak area as an ordinate; (3) preparing a to-be-detected sample solution; and (4) injecting the to-be-detected sample solution into a high performance liquid chromatograph for determination, recording the peak area of the to-be-detected sample solution, and calculating the content of the photodegradable impurities by using the standard curve. According to the method, high performance liquid chromatography is adopted, amino silane bonded silica gel is used as a stationaryphase, a mixed solution of acetonitrile and 0.05mol/L monopotassium phosphate solution is used as a mobile phase, and an isocratic elution mode is adopted. The method is high in specificity, high in precision, good in accuracy and capable of effectively detecting the content of photodegradation impurities in levofloxacin raw materials and preparations.

The invention relates to the fields of pharmaceutical analysis and traditional Chinese medicine identification and particularly relates to a trace identification method for natural Russian musk and natural forest musk. The method comprises a sample pretreatment step and a combined GC-MS chromatographic analysis and data treatment step. GC-MS color spectra of the natural Russian musk and the natural forest musk are contrastively analyzed, and the type of the musk can be determined by virtue of the significant difference of characteristic peaks of muscone in two types of musk and the comparisonof analysis data of the contents of muscone in two types of musk, so that the natural Russian musk and the natural forest musk can be conveniently, rapidly and accurately analyzed and judged. The operation specification and conditions of the method are specific, and the influence caused by the subjective factor of people is low, so that the accuracy and reliability of a result are remarkably improved; and furthermore, the method is simple, convenient and feasible, low in requirements on the professional level and practical experience of an operator and is vey suitable for being popularized andused in the field of pharmaceutical detection.

The invention relates to the field of drug detection, in particular to a method for detecting the residual quantity of amoxicillin and clavulanic acid in tissues, which comprises the following steps:1) preparing an amoxicillin and clavulanic acid reference substance solution and a to-be-detected tissue extract sample solution; 2) carrying out high performance liquid chromatography-tandem mass spectrometry detection, and quantifying by an external standard method or qualifying by a contrast method; wherein the chromatographic conditions are as follows: a chromatographic column is ACQUITYHSS T3, a mobile phase A is acetonitrile, and a mobile phase B is 0.1% formic acid water; wherein the mass spectrum conditions of amoxicillin detection comprise multi-reaction monitoring, positive ion scanning and capillary voltage of 3kV; mass spectrum conditions of clavulanic acid detection include multi-reaction monitoring, negative ion scanning and capillary voltage of-3kV. The method has good sensitivity, accuracy and precision, and qualitative and quantitative detection of amoxicillin and clavulanic acid residues is effectively realized.

The invention discloses a system for automatically detecting acute toxicity of chemicals to daphnia magna. The system comprises a toxicity prediction model QSAR, a microscopic operating system, an exposure system, a chemical storage system, a metering pump and a chemical determination system, wherein the exposure system comprises an exposure unit and an exposure parameter control interface. The invention also discloses a method for automatically detecting the acute toxicity of the chemicals to daphnia magna. The automatic method is established on the basis of an existing experimental method, and experimental workload is greatly reduced. A sensor is connected with a computer, conditions required for exposure are controlled more stably and accurately, and the device is equipped with an alarm system, so that experimental results are more accurate and reliable; the chemical concentration during exposure is controlled more accurately by a chemical detection unit; the activity of various behaviors of the daphnia magna is monitored more comprehensively and accurately, and the toxicity indication endpoint is judged more directly and accurately.